Acronyms of Clinical Trial Names: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| (11 intermediate revisions by 4 users not shown) | |||
| Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
''For other acronyms involved in clinical trials, click [[Clinical trial acronyms|here]]'' | ''For other acronyms involved in clinical trials, click [[Clinical trial acronyms|here]]'' | ||
| Line 11: | Line 11: | ||
{| cellspacing="1" cellpadding="1" border="1" | {| id="acronyms" cellspacing="1" cellpadding="1" border="1" | ||
| '''''Acronym''''' | | '''''Acronym''''' | ||
| '''''Trial Name''''' | | '''''Trial Name''''' | ||
| Line 964: | Line 964: | ||
|- | |- | ||
| [[CAPRICORN]] | | [[CAPRICORN]] | ||
| [[Carvedilol Post | | [[Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study]] | ||
|- | |- | ||
| [[CAPRIE]] | | [[CAPRIE]] | ||
| Line 1,025: | Line 1,022: | ||
| [[CARE-HD]] | | [[CARE-HD]] | ||
| [[Coenzyme Q10 And Remacemide: Evaluation In Huntington Disease]] | | [[Coenzyme Q10 And Remacemide: Evaluation In Huntington Disease]] | ||
|- | |- | ||
| [[CARE-HF]] | | [[CARE-HF]] | ||
| Line 1,036: | Line 1,030: | ||
|- | |- | ||
| [[CARESS-in-AMI: 30-Day and 1-Year Results]] | | [[CARESS-in-AMI: 30-Day and 1-Year Results]] | ||
| [[Combined Abciximab Reteplase Stent Study In Acute Myocardial Infarction]] | | [[Combined Abciximab Reteplase Stent Study In Acute Myocardial Infarction: 30-Day and 1-Year Results]] | ||
|- | |- | ||
| [[CARET]] | | [[CARET]] | ||
| Line 1,081: | Line 1,075: | ||
|- | |- | ||
| [[CAST]] | | [[CAST]] | ||
| [[Cardiac Arrhythmia Suppression Trial]] | |||
| [[Cardiac Arrhythmia Suppression Trial ]] | |||
|- | |- | ||
| [[CASTEMI]] | | [[CASTEMI]] | ||
| Line 1,092: | Line 1,083: | ||
| [[The Cardiac Arrhythmia Suppression Trial II]] | | [[The Cardiac Arrhythmia Suppression Trial II]] | ||
|- | |- | ||
| | | [[CASTLE]] | ||
| [[Candesartan Amlodipine Study Of Tolerability And Efficacy]] | | [[Candesartan Amlodipine Study Of Tolerability And Efficacy]] | ||
|- | |- | ||
| Line 1,118: | Line 1,109: | ||
| [[CAVATAS]] | | [[CAVATAS]] | ||
| [[Endovascular Versus Surgical Treatment In Patients With Carotid Stenosis In The Carotid And Vertebral Artery Transluminal Angioplasty Study (Cavatas)]] | | [[Endovascular Versus Surgical Treatment In Patients With Carotid Stenosis In The Carotid And Vertebral Artery Transluminal Angioplasty Study (Cavatas)]] | ||
|- | |- | ||
| [[CAVEAT I]] | | [[CAVEAT I]] | ||
| Line 1,128: | Line 1,116: | ||
| [[Coronary Angioplasty Versus Excisional Atherectomy Trial II]] | | [[Coronary Angioplasty Versus Excisional Atherectomy Trial II]] | ||
|- | |- | ||
| [CBT-CD]] | | [[CBT-CD]] | ||
| [[Cognitive Behavior Therapy For The Chronic Depressions]] | | [[Cognitive Behavior Therapy For The Chronic Depressions]] | ||
|- | |- | ||
| Line 1,187: | Line 1,175: | ||
| [[CHEESE]] | | [[CHEESE]] | ||
| [[Comparative Trial Of Hiv-Infected Patients Evaluating Efficacy And Safety Of Saquinavir-Enhanced Oral Formulation And Indinavir Given As Part Of A Triple Drug Therapy ]] | | [[Comparative Trial Of Hiv-Infected Patients Evaluating Efficacy And Safety Of Saquinavir-Enhanced Oral Formulation And Indinavir Given As Part Of A Triple Drug Therapy ]] | ||
|- | |- | ||
| [[CHF-STAT]] | | [[CHF-STAT]] | ||
| Line 1,199: | Line 1,184: | ||
| [[CHRISTMAS]] | | [[CHRISTMAS]] | ||
| [[Carvedilol Hibernating Reversible Ischaemia Trial]] | | [[Carvedilol Hibernating Reversible Ischaemia Trial]] | ||
|- | |- | ||
| [[CHS]] | | [[CHS]] | ||
| [[Cardiovascular Health Study]] | | [[Cardiovascular Health Study]] | ||
----- | |||
---- [[CHS]] | |||
---- [[Charleston Heart Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Community Health Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Congenital Heart Surgeons Society Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Coronary Heart Study]] | |||
|- | |- | ||
| [[CIAO]] | | [[CIAO]] | ||
| Line 1,219: | Line 1,210: | ||
|- | |- | ||
| [[CIBIS III]] | | [[CIBIS III]] | ||
| [[ | | [[The Cardiac Insufficiency Bisoprolol Study III]] | ||
|- | |- | ||
| [[CIDS]] | | [[CIDS]] | ||
| Line 1,238: | Line 1,229: | ||
| [[CLASS]] | | [[CLASS]] | ||
| [[Celecoxib (Celebrex) Long-Term Arthritis Safety Study]] | | [[Celecoxib (Celebrex) Long-Term Arthritis Safety Study]] | ||
|- | |- | ||
| [[CLASSICS]] | | [[CLASSICS]] | ||
| Line 1,252: | Line 1,240: | ||
|- | |- | ||
| [[CLEAR PLATELETS-2]] | | [[CLEAR PLATELETS-2]] | ||
| [[Clopidogrel With Eptifibatide To Arrest The Reactivity Of Platelets]] | | [[Clopidogrel With Eptifibatide To Arrest The Reactivity Of Platelets-2]] | ||
|- | |- | ||
| [[CLEERE]] | | [[CLEERE]] | ||
| Line 1,259: | Line 1,247: | ||
| [[COACH]] | | [[COACH]] | ||
| [[Coordinating Study Evaluating Outcomes Of Advising And Counseling In Heart Failure]] | | [[Coordinating Study Evaluating Outcomes Of Advising And Counseling In Heart Failure]] | ||
|- | |- | ||
| [[COAST]] | | [[COAST]] | ||
| Line 1,280: | Line 1,265: | ||
| [[COMBINE]] | | [[COMBINE]] | ||
| [[Combining Medications And Behavorial Interventions ]] | | [[Combining Medications And Behavorial Interventions ]] | ||
|- | |- | ||
| [[COMET]] | | [[COMET]] | ||
| Line 1,295: | Line 1,277: | ||
| [[COMMIT/CCS-2 – Metoprolol]] | | [[COMMIT/CCS-2 – Metoprolol]] | ||
| [[Randomized, Placebo-Controlled Trial Of Early Metoprolol In 46,000 Acute Myocardial Infarction Patients]] | | [[Randomized, Placebo-Controlled Trial Of Early Metoprolol In 46,000 Acute Myocardial Infarction Patients]] | ||
|- | |- | ||
| [[COMPANION]] | | [[COMPANION]] | ||
| Line 1,315: | Line 1,294: | ||
|- | |- | ||
| [[COMPLY]] | | [[COMPLY]] | ||
| [[Compliment Inhibition In Myocardial Infarction Treated With Thrombolytics | | [[Compliment Inhibition In Myocardial Infarction Treated With Thrombolytics (Evaluation Of Iv Dosing Regimens Of H5G1.1-Scfv) Sponsors]] | ||
|- | |- | ||
| [[COMS]] | | [[COMS]] | ||
| Line 1,324: | Line 1,303: | ||
|- | |- | ||
| [[CONSENSUS II]] | | [[CONSENSUS II]] | ||
| [[The Effects Of The Early Administration Of Enalapril On Mortality In Patients With Acute Myocardial Infarction: Results Of The Cooperative New Scandin]] | | [[The Effects Of The Early Administration Of Enalapril On Mortality In Patients With Acute Myocardial Infarction: Results Of The Cooperative New Scandin-2]] | ||
|- | |- | ||
| [[CONVERTIBLE]] | | [[CONVERTIBLE]] | ||
| Line 1,331: | Line 1,310: | ||
| [[CONVINCE]] | | [[CONVINCE]] | ||
| [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints Trial]] | | [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints Trial]] | ||
|- | |- | ||
| [[COOL]] | | [[COOL]] | ||
| Line 1,342: | Line 1,318: | ||
|- | |- | ||
| [[COOL MI]] | | [[COOL MI]] | ||
| [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | | [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | ||
|- | |- | ||
| Line 1,352: | Line 1,325: | ||
| [[COPERNICUS]] | | [[COPERNICUS]] | ||
| [[Effect Of Carvedilol On Survival In Severe Chronic Heart Failure]] | | [[Effect Of Carvedilol On Survival In Severe Chronic Heart Failure]] | ||
|- | |- | ||
| [[COPPA]] | | [[COPPA]] | ||
| Line 1,376: | Line 1,346: | ||
| [[COURAGE]] | | [[COURAGE]] | ||
| [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation ]] | | [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation ]] | ||
|- | |- | ||
| [[COURT]] | | [[COURT]] | ||
| [[Contrast Utilization In High Risk Patients Undergoing Ptca]] | | [[Contrast Utilization In High Risk Patients Undergoing Ptca]] | ||
|- | |- | ||
| [[C-PORT]] | | [[C-PORT]] | ||
| Line 1,418: | Line 1,382: | ||
| [[CRIS]] | | [[CRIS]] | ||
| [[A Controlled Trial Of Verapamil In Patients After Acute Myocardial Infarction: Results Of The Calcium, Antagonist Reinfarction Italian Study]] | | [[A Controlled Trial Of Verapamil In Patients After Acute Myocardial Infarction: Results Of The Calcium, Antagonist Reinfarction Italian Study]] | ||
|- | |- | ||
| [[CRUISE]] | | [[CRUISE]] | ||
| Line 1,472: | Line 1,433: | ||
| [[DATATOP]] | | [[DATATOP]] | ||
| [[Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism]] | | [[Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism]] | ||
|- | |- | ||
| [[DAVID]] | | [[DAVID]] | ||
| Line 1,496: | Line 1,454: | ||
| [[DEBATE]] | | [[DEBATE]] | ||
| [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | | [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | ||
|- | |- | ||
| [[DEBATE II]] | | [[DEBATE II]] | ||
| [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | | [[Doppler Endpoints Balloon Angioplasty Trial Europe-2]] | ||
|- | |- | ||
| [[DEBUT]] | | [[DEBUT]] | ||
| Line 1,547: | Line 1,502: | ||
| [[DETAIL]] | | [[DETAIL]] | ||
| [[Diabetics Exposed To Telmisartan And Enalapril]] | | [[Diabetics Exposed To Telmisartan And Enalapril]] | ||
|- | |- | ||
| [[DIABETES]] | | [[DIABETES]] | ||
| Line 1,586: | Line 1,538: | ||
| [[DIG Enalapril]] | | [[DIG Enalapril]] | ||
| [[Enalapril Versus Digoxin In Patients With Congestive Heart Failure: A Multicenter Study (Canadian Enalapril Versus Digoxin Study Group)]] | | [[Enalapril Versus Digoxin In Patients With Congestive Heart Failure: A Multicenter Study (Canadian Enalapril Versus Digoxin Study Group)]] | ||
|- | |- | ||
| [[DIGAMI]] | | [[DIGAMI]] | ||
| Line 1,787: | Line 1,736: | ||
| [[ENABLE]] | | [[ENABLE]] | ||
| [[Effects Of The Endothelin Receptor Antagonist Bosentan On The Morbidity And Mortality In Patients With Chronic Heart Failure]] | | [[Effects Of The Endothelin Receptor Antagonist Bosentan On The Morbidity And Mortality In Patients With Chronic Heart Failure]] | ||
|- | |- | ||
| [[ENCOR]] | | [[ENCOR]] | ||
| [[Enrasentan Cooperative Randomized Evaluation]] | | [[Enrasentan Cooperative Randomized Evaluation]] | ||
|- | |- | ||
| [[ENCORE I]] | | [[ENCORE I]] | ||
| Line 1,807: | Line 1,750: | ||
|- | |- | ||
| [[ENDEAVOR III]] | | [[ENDEAVOR III]] | ||
| [[Randomized Comparison Of Zotarolimus-Eluting And Sirolimus-Eluting Stents In Patients With Coronary Artery Disease]] | | [[Randomized Comparison Of Zotarolimus-Eluting And Sirolimus-Eluting Stents In Patients With Coronary Artery Disease-3]] | ||
|- | |- | ||
| [[ENDEAVOR IV]] | | [[ENDEAVOR IV]] | ||
| [[Randomized Comparison Of Zotarolimus-Eluting And Paclitaxel-Eluting Stents In Patients With Coronary Artery Disease]] | | [[Randomized Comparison Of Zotarolimus-Eluting And Paclitaxel-Eluting Stents In Patients With Coronary Artery Disease-4]] | ||
|- | |- | ||
| [[ENDEAVOR-1]] | | [[ENDEAVOR-1]] | ||
| Line 1,820: | Line 1,763: | ||
| [[ENRICHD]] | | [[ENRICHD]] | ||
| [[Enhancing Recovery In Coronary Heart Disease]] | | [[Enhancing Recovery In Coronary Heart Disease]] | ||
|- | |- | ||
| [[ENTIRE]] | | [[ENTIRE]] | ||
| Line 1,835: | Line 1,775: | ||
| [[EPHESUS]] | | [[EPHESUS]] | ||
| [[Eplerenone Post-Ami Heart Failure Efficacy And Survival Study]] | | [[Eplerenone Post-Ami Heart Failure Efficacy And Survival Study]] | ||
|- | |- | ||
| [[EPIC]] | | [[EPIC]] | ||
| [[Evaluation Of C7E3 For The Prevention Of Ischemic Complications]] | | [[Evaluation Of C7E3 For The Prevention Of Ischemic Complications]] | ||
|- | |- | ||
| [[EPILOG]] | | [[EPILOG]] | ||
| [[Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade]] | | [[Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade]] | ||
|- | |- | ||
| [[EPISTENT]] | | [[EPISTENT]] | ||
| Line 1,947: | Line 1,878: | ||
| [[Exercise Training Intervention After Coronary Angioplasty: The Etica Trial]] | | [[Exercise Training Intervention After Coronary Angioplasty: The Etica Trial]] | ||
|- | |- | ||
| | | [[ETROP]] | ||
| [[Early Treatment Of Retinopathy Of Prematurity]] | | [[Early Treatment Of Retinopathy Of Prematurity]] | ||
|- | |- | ||
Latest revision as of 20:38, 8 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For other acronyms involved in clinical trials, click here
For detailed instructions on how to contribute to WikiDoc's Clinical Trials Wiki, click here